Clene Sets Early Q4 NDA Filing for ALS Drug, Delaying from Prior Year-End Target

What happened

Clene (CLNN) announced it will submit an NDA for CNM-Au8 in ALS in early Q4 2026, following productive FDA meetings that resolved some regulatory uncertainties. The update pushes the filing beyond the company’s earlier end-2025 timeline, reflecting the FDA’s prior insistence on definitive clinical outcomes beyond biomarker data. While the defined roadmap marks progress, Clene still faces a going-concern warning and must secure non-dilutive funding to finance the confirmatory RESTORE-ALS trial. The withdrawal of Relyvrio creates a commercial opening, but success hinges on convincing the FDA of efficacy. The filing milestone is a tangible step, yet substantial financial and clinical risks remain.

Implication

The year-long delay suggests more rigorous FDA scrutiny, potentially strengthening the data package but extending the cash burn. Without near-term financing, dilution or insolvency looms, especially with only ~$7M in cash as of mid-2025 and steep quarterly losses. If the NDA is accepted and accelerated approval secured, shares could re-rate dramatically, but historical FDA caution and the necessity of a successful confirmatory trial temper upside. The post-Relyvrio ALS landscape offers opportunity, but only for a drug with clear efficacy. Investors should watch for a partnership or capital raise concurrent with the filing to de-risk the thesis.

Thesis delta

The NDA timeline shifts from a vague end-2025 target to a concrete early Q4 2026 filing, reducing regulatory ambiguity but underscoring a year’s delay. Financing risk remains acute, and the confirmatory trial is still unfunded. The thesis upgrades from Neutral to Speculative Buy, contingent on the company securing non-dilutive capital near-term.